Evaluation of Bevacizumab in Advanced Small Bowel Adenocarcinoma

Aydin D., Sendur M. A., KEFELİ U., Ustaalioglu B. B., Aydin O., Yildirim E., ...More

CLINICAL COLORECTAL CANCER, vol.16, no.1, pp.78-83, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 16 Issue: 1
  • Publication Date: 2017
  • Doi Number: 10.1016/j.clcc.2016.04.013
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.78-83
  • Kütahya Health Sciences University Affiliated: No


Small bowel adenocarcinomas (SBAs) are rarely seen tumors of the gastrointestinal system. Data on the usage of chemotherapy together with bevacizumab in SBAs is limited. We analyzed the results of treatment with bevacizumab with or without chemotherapy in 28 patients with SBAs. Although there was a trend toward a survival benefit, we did not find any statistically significant difference with the addition of bevacizumab to the backbone chemotherapy in SBAs.